Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 29 08 2018
accepted: 25 01 2019
entrez: 13 2 2019
pubmed: 13 2 2019
medline: 8 11 2019
Statut: epublish

Résumé

The aim of this paper was to describe the time trends in the prevalence of multimorbidity and polypharmacy in Flanders (Belgium) between 2000 and 2015, while controlling for age and sex. Data were available from Intego, a Flemish-Belgian general practice-based morbidity registration network. The practice population between 2000 and 2015 was used as the denominator, representing a mean of 159,946 people per year. Age and gender-standardised prevalence rates were used for the trends of multimorbidity and polypharmacy in the total population and for subgroups. Joinpoint regression analyses were used to analyse the time trends and breaks in trends, for the entire population as well as for specific age and sex groups. Overall, in 2015, 22.7% of the population had multimorbidity, while the overall prevalence of polypharmacy was 20%. Throughout the study period the standardised prevalence rate of multimorbidity rose for both sexes and in all age groups. The largest relative increase in multimorbidity was observed in the younger age groups (up to the age of 50 years). The prevalence of polypharmacy showed a significant increase between 2000 and 2015 for all age groups except the youngest (0-25 years). For all adult age groups multimorbidity and polypharmacy are frequent, dynamic over time and increasing. This asks for both epidemiological and interventional studies to improve the management of the resulting complex care.

Identifiants

pubmed: 30753214
doi: 10.1371/journal.pone.0212046
pii: PONE-D-18-25398
pmc: PMC6372187
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0212046

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
J Comorb. 2015 Apr 24;5:29-31
pubmed: 29090158
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
Eur Respir J. 2014 Oct;44(4):1055-68
pubmed: 25142482
Health Qual Life Outcomes. 2004 Sep 20;2:51
pubmed: 15380021
Arch Gerontol Geriatr. 2016 Nov-Dec;67:130-8
pubmed: 27500661
Ann Fam Med. 2017 Nov;15(6):546-551
pubmed: 29133494
J Gerontol A Biol Sci Med Sci. 2015 Aug;70(8):989-95
pubmed: 25733718
BMC Med. 2014 Dec 08;12:223
pubmed: 25484244
BMJ. 2013 May 02;346:f2510
pubmed: 23641032
Fam Pract. 1992 Mar;9(1):15-21
pubmed: 1634021
BMC Med Inform Decis Mak. 2014 Jun 06;14:48
pubmed: 24906941
Lancet. 2015 Feb 14;385(9968):587-589
pubmed: 25468155
Eur J Gen Pract. 2008;14 Suppl 1:28-32
pubmed: 18949641
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006560
pubmed: 22513941
Risk Manag Healthc Policy. 2016 Jul 05;9:143-56
pubmed: 27462182
Ageing Res Rev. 2017 Aug;37:53-68
pubmed: 28511964
BMJ. 2009 Aug 11;339:b2803
pubmed: 19671932
NCHS Data Brief. 2012 Jul;(100):1-8
pubmed: 23101759
Eur J Ageing. 2015 Jul 23;12(4):285-297
pubmed: 28804361
PLoS One. 2016 Aug 02;11(8):e0160264
pubmed: 27482903
Healthcare (Basel). 2015 Jan 29;3(1):50-63
pubmed: 27417747
Ann Fam Med. 2012 Mar-Apr;10(2):142-51
pubmed: 22412006
J Clin Epidemiol. 2001 Jul;54(7):675-9
pubmed: 11438407
J Comorb. 2016 Aug 26;6(2):85-94
pubmed: 29090179
Br J Clin Pharmacol. 2007 Feb;63(2):136-47
pubmed: 16803468
Popul Health Manag. 2018 Apr;21(2):123-129
pubmed: 28683221
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
BMJ. 2004 Jul 3;329(7456):15-9
pubmed: 15231615
Fam Pract. 2005 Aug;22(4):442-7
pubmed: 15964863
Prev Chronic Dis. 2015 Nov 12;12:E197
pubmed: 26564013
BMC Fam Pract. 2017 Jan 17;18(1):5
pubmed: 28095780
BMC Med. 2015 Apr 07;13:74
pubmed: 25889849
BMJ Open. 2015 Feb 03;5(2):e006413
pubmed: 25649210
BMC Health Serv Res. 2017 Nov 21;17(1):754
pubmed: 29162094
Clin Teach. 2016 Aug;13(4):291-7
pubmed: 26840754
Eur J Public Health. 2018 Feb 1;28(1):193-198
pubmed: 29016831

Auteurs

Marjan van den Akker (M)

Department of Family Medicine, School Caphri, Maastricht University, Maastricht, the Netherlands.
Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.

Bert Vaes (B)

Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.

Geert Goderis (G)

Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.

Gijs Van Pottelbergh (G)

Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.

Tine De Burghgraeve (T)

Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.

Séverine Henrard (S)

Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium.
Louvain Drug Research Institute and Institute of Health and Society (IRSS), Université catholique de Louvain (UCL), Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH